News
Omnix Medical Receives U.S. FDA Approval of a Phase II Trial of its Next-Generation Anti-Infective OMN6
– Phase I data show safety and tolerability at clinically significant dose levels
– New class of anti-infectives to treat infections with Gram-negative bacteria
Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced that the U.S. Food and Drug Administration (FDA) has approved a planned Phase II trial of the Company´s novel anti-infective OMN6.
Dr. Hartmut Tintrup Joins Cellbox Solutions GmbH as New CEO
– Seasoned business development professional joins from Lonza
Cellbox Solutions GmbH, a leading provider of live cell logistics solutions for research, development and shipment of cell-based therapies and cellular diagnostics, today announced that Dr. Hartmut Tintrup has joined Cellbox Solutions GmbH as Chief Executive Officer. Hartmut joins the Cellbox team from Lonza, where he served as Global Head Business Development in the Cell & Gene Technologies Business Unit. He brings more than 20 years of international business experience in life science organizations across the U.S. and Europe, including leadership positions at Exelixis, Inc. and CEVEC Pharmaceuticals GmbH. Hartmut received his doctorate degree in Neurochemistry from Goethe University Frankfurt. Read more…
BellaSeno Presents Novel Production Workflow for Customized, 3D-Printed Bone Scaffolds
— Presentation at the German Congress of Orthopaedics and Traumatology (DKOU)
— Treatment of large segmental bone defects with resorbable scaffolds
— Leading-edge workflow for the design and manufacturing of customized bone scaffolds
BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, today announced that the Company has presented novel data on the design and manufacturing of customized, 3D-printed bone scaffolds at the recent German Congress of Orthopaedics and Traumatology (DKOU).
MetrioPharm Receives Rare Pediatric Disease Designation (RPDD) for MP1032 from the U.S. FDA
— FDA grants RPDD for the treatment of Duchenne muscular dystrophy (DMD)
— MetrioPharm may be eligible for a priority review voucher with a market value in excess of USD 100 million
— MetrioPharm has recently raised CHF 18 million for the development of MP1032 in DMD in a Series D round and is targeting a second closing
MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory and infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) for MP1032 for the treatment of Duchenne muscular dystrophy.